scholarly journals Rituximab treatment results in impaired secondary humoral immune responsiveness

Blood ◽  
2002 ◽  
Vol 100 (6) ◽  
pp. 2257-2259 ◽  
Author(s):  
Lizet E. van der Kolk ◽  
Joke W. Baars ◽  
Martin H. Prins ◽  
Marinus H. J. van Oers

Abstract In lymphoma patients, treatment with chimeric CD20 monoclonal antibodies (rituximab) results in a depletion of normal and malignant B cells, persisting for 6 to 9 months. This B-cell depletion leads neither to a decrease in immunoglobulin levels nor an increase in the number of infectious complications. However, the effect of rituximab treatment on the immune responsiveness is unknown. In 11 patients with relapsed, low-grade lymphoma, we investigated the effect of rituximab treatment on the humoral immune response to 2 primary antigens and 2 recall antigens. After rituximab treatment, the humoral immune response to the recall antigens was significantly decreased when compared with the response before treatment. Already before rituximab treatment, none of these patients was able to mount a response to the primary antigens. These findings are relevant regarding the feasibility of rituximab in maintenance treatment and may also offer a rationale for the treatment of antibody-mediated autoimmune diseases with rituximab.

Blood ◽  
2002 ◽  
Vol 100 (6) ◽  
pp. 2257-2259 ◽  
Author(s):  
Lizet E. van der Kolk ◽  
Joke W. Baars ◽  
Martin H. Prins ◽  
Marinus H. J. van Oers

In lymphoma patients, treatment with chimeric CD20 monoclonal antibodies (rituximab) results in a depletion of normal and malignant B cells, persisting for 6 to 9 months. This B-cell depletion leads neither to a decrease in immunoglobulin levels nor an increase in the number of infectious complications. However, the effect of rituximab treatment on the immune responsiveness is unknown. In 11 patients with relapsed, low-grade lymphoma, we investigated the effect of rituximab treatment on the humoral immune response to 2 primary antigens and 2 recall antigens. After rituximab treatment, the humoral immune response to the recall antigens was significantly decreased when compared with the response before treatment. Already before rituximab treatment, none of these patients was able to mount a response to the primary antigens. These findings are relevant regarding the feasibility of rituximab in maintenance treatment and may also offer a rationale for the treatment of antibody-mediated autoimmune diseases with rituximab.


2014 ◽  
Vol 21 (3) ◽  
pp. 407-416 ◽  
Author(s):  
Feng Yang ◽  
Qiuyue Ma ◽  
Liancheng Lei ◽  
Jing Huang ◽  
Qun Ji ◽  
...  

ABSTRACTPorcine contagious pleuropneumonia, caused byActinobacillus pleuropneumoniae, has a major impact on economics, ecology, and animal welfare in the pig-rearing industry.Propionibacterium acnes, a facultative anaerobic Gram-positive corynebacterium, exists widely in normal healthy adult animals. We have shown previously thatP. acnescan preventA. pleuropneumoniaeinfections in mice and pigs. To elucidate the mechanism of this effect and to identify novelA. pleuropneumoniaevaccines, the role of anti-P. acnesantibodies in preventing infection was analyzed by indirect immunofluorescence and opsonophagocytosis assaysin vitro. The role of the specific humoral immune response induced byP. acneswas confirmed in a B cell depletion mouse model. The survival rates of mice challenged withA. pleuropneumoniaeexhibited a highly significant positive rank correlation with the levels of anti-P. acnesantibodies. The specific antibodies induced byP. acneshad the ability to combine withA. pleuropneumoniaeand increase opsonization ofA. pleuropneumoniaefor phagocytosis. Furthermore, analysis in the murine B cell depletion model confirmed that the humoral immune response induced byP. acnesplayed an important role in resistance toA. pleuropneumoniaeinfection. In this study, we further elucidated the reasons thatP. acnescan preventA. pleuropneumoniaeinfection, which provides useful evidence for the development of heterologous vaccines for the control of porcine contagious pleuropneumonia.


2009 ◽  
Vol 54 (3) ◽  
pp. 239-245 ◽  
Author(s):  
J. M. L. Maia ◽  
L. G. S. Monnazzi ◽  
B. M. M. Medeiros

2021 ◽  
pp. 113043
Author(s):  
Marnix Mylemans ◽  
Eveline Van Honacker ◽  
Louis Nevejan ◽  
Stefanie van den Bremt ◽  
Laura Hofman ◽  
...  

2021 ◽  
Vol 6 (1) ◽  
pp. e000733
Author(s):  
Astrid Muyldermans ◽  
Maria Bjerke ◽  
Thomas Demuyser ◽  
Deborah De Geyter ◽  
Ingrid Wybo ◽  
...  

Background/aimsSARS-CoV-2 is highly contagious. More evidence concerning extrapulmonary transmission routes such as the eyes is urgently needed. Although the humoral immune response is important in the viral containment, the local response in tears has not yet been studied. The aim of our study was twofold: to assess the prevalence of both SARS-CoV-2 RNA and antibodies in tear fluid.MethodsIn a first series, nasopharyngeal sampling and tear sampling by Schirmer test strips were performed in 26 acutely ill patients with COVID-19 to assess the presence of SARS-CoV-2 RNA by reverse transcription PCR. In a second series, IgG and IgA responses to SARS-CoV-2 spike protein in serum and tear fluid of convalescent individuals (n=22) were compared with control individuals (n=15) by ELISA.ResultsSARS-CoV-2 RNA was detected in tears of 7/26 (26.9%) patients with COVID-19. None of them had ocular symptoms. Convalescent individuals displayed a significant higher ratio of IgG (p<0.0001) and IgA (p=0.0068) in tears compared with control individuals. A sensitivity of 77.3% and specificity of 93.3% was observed for IgG, and 59.1% and 100% for IgA.ConclusionsOur results demonstrate the presence of SARS-CoV-2 RNA and a local IgG and IgA immune response in tear fluid. These data confirm the possibility of SARS-CoV-2 transmission through tear fluid and the importance of the eye as a first defence against SARS-CoV-2, indicating the potential of tears as a non-invasive surrogate for serum in monitoring the host immune response.


Animals ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 2231
Author(s):  
István Kiss ◽  
Krisztina Szigeti ◽  
Zalán G. Homonnay ◽  
Vivien Tamás ◽  
Han Smits ◽  
...  

Piglets from a porcine circovirus type 2 (PCV2) stable farm of low and high levels of maternally derived antibodies (MDA) against PCV2 were vaccinated either with a whole virus type or a PCV2 ORF2 antigen-based commercial subunit vaccine at three weeks of age. Two non-vaccinated groups served as low and high MDA positive controls. At four weeks post vaccination, all piglets were challenged with a PCV2d-2 type virus strain and were checked for parameters related to vaccine protection over a four-week observation period. MDA levels evidently impacted the outcome of the PCV2d-2 challenge in non-vaccinated animals, while it did not have a significant effect on vaccine-induced protection levels. The humoral immune response developed faster in the whole virus vaccinates than in the subunit vaccinated pigs in the low MDA groups. Further, high MDA levels elicited a stronger negative effect on the vaccine-induced humoral immune response for the subunit vaccine than for the whole virus vaccine. The group-based oral fluid samples and the group mean viraemia and faecal shedding data correlated well, enabling this simple, and animal welfare-friendly sampling method for the evaluation of the PCV2 viral load status of these nursery piglets.


Sign in / Sign up

Export Citation Format

Share Document